1. FRI0065 Proteomic Profiling Following Immunoaffinity Capture of High-Density Lipoprotein (HDL) Identifies Changes in Multiple HDL-Associated Proteins Following Treatment with Abatacept or Adalimumab in the Ample Study of Patients with Rheumatoid Arthritis. (9th June 2015) Authors: Charles-Schoeman, C.; Gugiu, G.B.; Ge, H.; Shahbazian, A.; Lee, Y.Y.; Wang, X.; Furst, D.E.; Ranganath, V.K.; Maldonado, M.; Reddy, S.T. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0154 Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with A Cumulative Exposure of 12, 664 Patient-Years. (10th June 2014) Authors: Cohen, S.; Tanaka, Y.; Mariette, X.; Curtis, J.; Kwok, K.; Lee, E.; Nash, P.; Winthrop, K.; Charles-Schoeman, C.; Thirunavukkarasu, K.; Anisfeld, A.; Wang, L.; Riese, R.; Wollenhaupt, J. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. (August 2018) Authors: Charles-Schoeman, C.; Gugiu, G.B.; Ge, H.; Shahbazian, A.; Lee, Y.Y.; Wang, X.; Furst, D.E.; Ranganath, V.K.; Maldonado, M.; Lee, Terry; Reddy, S.T. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. (12th June 2018) Authors: Mease, P.J.; Kremer, J.; Cohen, S.; Curtis, J.R.; Charles-Schoeman, C.; Loftus, E.V.; Greenberg, J.; Palmetto, N.; Kanik, K. S.; Graham, D.; Wang, C.; Biswas, P.; Chan, G.; DeMasi, R.; Valdez, H.; Hendrikx, T.; Jones, T. V. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 983 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0136 Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690, 550), a novel, oral jak inhibitor. (23rd January 2014) Authors: Charles-Schoeman, C.; Wicker, P.; Sechtem, U.; Gonzalez-Gay, M.A.; Wood, S.; Boy, M.; Geier, J.; Gruben, D.; Soma, K.; Riese, R.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies. (12th June 2018) Authors: Gladman, D.D.; Charles-Schoeman, C.; McInnes, I.B.; Veale, D.J.; Thiers, B.; Graham, D.; Wang, C.; Jones, T.V.; Wolk, R.; DeMasi, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗